This is a case of one patient sample resulted (b)(6) with advia centaur xp anti-hbs2 reagent lot 119098.However, obtained (b)(6) result with repeat testing using the same sample tube.Patient is (b)(6) with (b)(6) biomarkers.There is no indication of patient receive (b)(6) vaccination.Additionally, there was no evidence of fibrin in the sample.The customer service engineer (cse) was at the customer site investigating another issue.The cse decontaminated the analyzer and determined contamination tests are okay.Post-service, a (b)(6) result was obtained upon repeating the affected patient sample with anti-hbs2 assay.Based on the information available, there may have been non-specific interference between sample and reagent giving (b)(6) result.The advia centaur xp anti-hbs2 ous instruction for use (ifu) (10629819_en rev.K, 2017-12) states under interpretation of results section "nonreactive: samples with an initial value of less than 8 miu/ml are considered nonreactive (negative) for antibodies to hbsag." further repeat testing is not required as per assay ifu.Review of in-house data shows the performance of lot 119098 met all release criteria.The instrument is performing within specifications.No further evaluation of the device is required.
|